Is there a generic version of durvalumab? What is the difference in effectiveness and price between generic and genuine drugs?

There are currently no generic versions of durvalumab on the market. Although this drug has been marketed in China and is used to treat certain immune-related diseases, because it is a biological agent, the development and approval cycle of generic drugs is usually long, so its generic drugs have not yet been launched. Generic drugs of biopharmaceutical drugs such as durvalumab usually require strict clinical verification during the production process to ensure the similarity between the generic drug and the original drug. Especially in the field of immunotherapy, any subtle differences may affect the efficacy and safety of the drug.

The generic durvalumab currently available on the market is relatively expensive. Common specifications are 120mg/2.4mL and 500mg/10mL. The price of a single box may be as high as 4,000 to more than 10,000 yuan, which is a considerable burden for many patients. Since the drug is not yet covered by medical insurance, patients need to pay for it out of pocket, which further increases the pressure on treatment costs. In addition, in overseas markets, the price of original drugs is relatively high. 120mg/2.4mL is often sold for more than a thousand US dollars, which shows the high cost of biological drugs.

The emergence of generic drugs usually brings significant price reductions; however, there are currently no generic versions of durvalumab available. If a future generic version of the drug can pass rigorous clinical trials and gain regulatory approval, the price could be significantly reduced, increasing affordability for patients. Generic drugs are often cheaper than originator drugs; however, consistency in quality and efficacy of generic drugs must be ensured through rigorous bioequivalence testing, especially for immunotherapy drugs.

In general, although there are currently no generic drugs of durvalumab on the market, patients can communicate with their doctors to find out whether there are other similar immunotherapy drugs that can be used instead. If generic drugs are launched in the future, patients can choose appropriate treatment options based on their own conditions to reduce the economic burden of drug treatment. But before that, patients should choose drugs carefully to ensure the effectiveness and safety of the treatment.

Reference materials:https://www.imfinzi.com/